美股市場個股詳情

AFCG AFC Gamma

添加自選

12.210
+0.010+0.08%

收盤價 05/03 16:00 (美東)

12.330
+0.120+0.98%

盤後 17:30 (美東)

2.52億總市值11.97市盈率TTM

AFC Gamma股票討論區

登錄發表評論

逍遥投资派

04/13 00:08

$AFC Gamma(AFCG.US)$ 🎯 2024.4.12 當前價格11.71，持倉浮虧3%
新增數據：23Q3，23Q4，淨利潤連續萎縮，Q4受信貸損失準備金影響轉爲虧損。
2023年淨利潤萎縮到0.21億，市盈率爲11.5，3年平均淨利0.26億對應市盈率9.3，股息率17%，回報率吸引力不大。

已翻譯

Moomoo AI

03/26 20:43

AFC Gamma's CEO sees Sunburn poised to gain more market share in Florida and profit from the industry's shift to mainstream consumer goods. Sunburn's CEO sees this as a chance to bolster their balance sheet, expand operations, and enhance Sunburn while awaiting potential catalysts.

Press Release: AFC Gamma Provides Sunburn Cannabis With a Total of $34.0 Million Across Senior Secured Credit Facilities

Moomoo AI

02/08 05:10

AFC Gamma's CEO, Daniel Neville, expressed excitement about the two loans, stating they align with the company's strategy to invest in high-quality commercial real estate deals that provide compelling risk-adjusted returns.

Press Release: AFC Gamma Closes Two Syndicated Commercial Real Estate Loans

Wacho-el-Wero

01/21 13:57

10 please

$AFC Gamma(AFCG.US)$

Moomoo AI

2023/10/30 20:37

Tannenbaum expects Neville's knowledge and leadership in the cannabis sector to boost AFC Gamma, particularly in managing cannabis credits. Neville sees growth potential for AFC Gamma through capital deployment and expanded platforms.

Press Release: AFC Gamma, Inc. Announces Appointment of Daniel Neville as New Chief Executive Officer

逍遥投资派

2023/09/19 00:13

$AFC Gamma(AFCG.US)$是爲大麻經營者做房地產融資的公司，其實應該分入抵押貸款板塊。
2021年上市，股息率TTM爲16.5%，上市後發放比較穩定，市淨率目前0.79。
2022年營收增長87.9%，淨利潤增長71.1%，2023上半年營收萎縮14.9%，淨利潤增長3%。
市盈率TTM爲7.34，市盈率7.3，按近兩年平均淨利0.28億計算，市盈率爲9.5，不算太高。
綜合來看可以謹慎選擇(⭐️)

已翻譯

Moomoo Breakfast US

2022/04/06 20:42

專欄Today's pre-market stock movers: ARRY, RIOT, MRNA, NVAX and more

Gainers:
• $Array Technologies(ARRY.US)$ +12.87% (also names new CEO)
• $Tufin軟件科技(TUFN.US)$ +43.41% (enters into definitive agreement to be acquired by Turn/River Capital in a $570 million transaction; TUFN shareholders will receive $13.00/share in cash)
• $Citius Pharmaceuticals(CTXR.US)$ +10.87% (reported topline results from the pivotal Phase 3 trial of I/ONTAK)
• $BioXcel Therapeutics(BTAI.US)$ +19.22% (FDA ha...